Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

FIBROTARGET

Financiado

Validation of novel immunotherapeutic targets against fibrosis in inflammatory b...

Validation of novel immunotherapeutic targets against fibrosis in inflammatory bowel diseases Fibrostenosis is the driving reason for the persistent need in bowel resections in inflammatory bowel diseases (IBD). Current IBD therapies are limited to solely targeting inflammation. While these therapies in some, but not all,... ver más

31/03/2028

KU Leuven

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 10 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-04-24

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

HORIZON-HLTH-2022-DISEASE-06-02-two-stage: Pre-clinical development of the next generation of immunotherapies for diseases or disorders with unmet medical needs

I+D

Cerrada hace 2 años

0% 100%

10 Participantes

KU Leuven

2.44M€ | Lider

AMYNDAS PHARMACEUTICALS SING...

400.63K€ | Participante

MOTILENT LIMITED

N.D. | Participante

TEAMIT INSTITUTE S L

35.00K€ | Participante

Proyectos interesantes

iMOTIONS Immune-stromal crosstalk in inflammation and fibrosis: Explo... 1M€ Cerrado

SAF2008-03676 ESTUDIO DE LA FIBROGENESIS INTESTINAL EN LA ENFERMEDAD DE CR... 85K€ Cerrado

BFU2008-02683 NUEVOS MEDIADORES DE LA RESPUESTA T EFECTORA Y POTENCIAL TER... 121K€ Cerrado

SAF2011-29435 FIBROGENESIS Y ENFERMEDAD DE CROHN. ESTUDIO DE LOS MECANISMO... 121K€ Cerrado

SAF2016-80072-P MODULACION DE LA FIBROSIS INTESTINAL POR EL SISTEMA INMUNE I... 121K€ Cerrado

INTERCONNECTIONS Interplay of epithelial mechanics and neutrophil activation... 174K€ Cerrado

Últimas noticias

27-11-2024: Videojuegos y creaci... Se abre la línea de ayuda pública: Ayudas para la promoción del sector del videojuego, del pódcast y otras formas de creación digital

27-11-2024: DGIPYME En las últimas 48 horas el Organismo DGIPYME ha otorgado 1 concesiones

27-11-2024: FUNDACION-EOI En las últimas 48 horas el Organismo FUNDACION EOI ha otorgado 2 concesiones

Duración del proyecto: 59 meses Fecha Inicio: 2023-04-24
Fecha Fin: 2028-03-31

Líder del proyecto

KATHOLIEKE UNIVERSITEIT LEUVEN

TRL 4-5

Presupuesto del proyecto 6M€

Descripción del proyecto Fibrostenosis is the driving reason for the persistent need in bowel resections in inflammatory bowel diseases (IBD). Current IBD therapies are limited to solely targeting inflammation. While these therapies in some, but not all, cases lead to symptomatic disease remission, recurrent flares interspaced with periods of remission will still result in cumulative gut wall remodeling and fibrosis. Indeed, despite these therapeutic strategies to control inflammation, fibrostenosis incidence and bowel surgical resection is not declining in IBD patients, as no anti-fibrotic drugs are currently available. The aim of this project is to validate fibroblast therapeutic targets for preventing and/or treating fibrosis in IBD-patient-samples with an emphasis on C3 and/or Tyk2/STAT3 and/or NLRP3 in the evolution of intestinal fibrosis. The anti-fibrotic efficacy and mode of action of these novel immunotherapies will be studied preclinically in IBD-patient derived samples and validated in animal models of chronic colitis. In parallel, we aim to develop and validate a clinical diagnostic and prognostic pathway for fibrosis in IBD patients based on the use of non-invasive cross-sectional imaging techniques such as magnetic resonance enterography with elastography and optoacoustic. These results together will allow to design a first-in-human proof of concept randomized trial of immunotherapeutic drugs targeting complement C3 and/or Tyk2/STAT3 and/or NLRP3 pathways in intestinal fibrostenosis. Our aim is to obtain patients and regulatory approval for implementation of these novel non-invasive imaging modalities as diagnostic and prognostic tools for fibrotic IBD to allow vital future therapeutic development for intestinal fibrosis. By providing better molecular and clinical stratification of IBD patients at risk for fibrosis and by identifying and validating novel targets for anti-fibrotic therapy, we aim to pave the way in preventing and treating this invalidating IBD comorbidity.

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores